GSK — GLAXOSMITHKLINE PLC

Ownership history in Bayesian Capital Management, LP  ·  10 quarters on record

This page tracks every 13F SEC filing in which Bayesian Capital Management, LP reported a position in GLAXOSMITHKLINE PLC (GSK). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.43% (2015 Q4)
Avg. % of fund
0.18%
First filed
2015 Q4
Last filed
2025 Q3
Quarters held
10
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 REDUCED 10,295 -5,542 -35.0% 0.09% $444K $42.44
2025 Q1 ADDED 15,837 +1,800 +12.8% 0.10% $614K $37.25
2024 Q4 ADDED 14,037 +3,537 +33.7% 0.06% $475K $32.17
2023 Q2 REDUCED 10,500 -13,820 -56.8% 0.04% $374K $31.96
6 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    GSK price (monthly, adj. close)

Other funds also holding GSK

As of 2025 Q4 — sorted by position size

Eversept Partners, LP 3Y 7Y 6.62% Mondrian Investment Partners LTD 3Y 7Y 4.7% EQUITY INVESTMENT CORP 3Y 7Y 4.07% Callodine Capital Management, LP 3Y 7Y 3.96% Hillman Capital Management, Inc. 3Y 7Y 3.53% KEATING INVESTMENT COUNSELORS INC 3Y 7Y 2.45% MILLER HOWARD INVESTMENTS INC /NY 3Y 7Y 2.43% Clean Yield Group 3Y 7Y 2.2% NIA IMPACT ADVISORS, LLC 3Y 2.08% Altrius Capital Management Inc 3Y 2.05%
← Back to Bayesian Capital Management, LP Holdings